Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
R&D Expenses Over TimeContracting
Percentile Rank80
3Y CAGR-3.5%
5Y CAGR+5.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-3.5%/yr
vs +7.9%/yr prior
5Y CAGR
+5.3%/yr
Recent deceleration
Acceleration
-11.3pp
Decelerating
Percentile
P80
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $20.82M | -30.7% |
| 2024 | $30.05M | -22.3% |
| 2023 | $38.67M | +67.1% |
| 2022 | $23.14M | +32.1% |
| 2021 | $17.51M | +8.8% |
| 2020 | $16.09M | -2.8% |
| 2019 | $16.55M | -3.2% |
| 2018 | $17.09M | -3.4% |
| 2017 | $17.70M | +1.1% |
| 2016 | $17.50M | - |